Stable human brain microvascular endothelial cell line retaining its barrier-specific nature independent of the passage number

Clinical and Experimental Neuroimmunology

Volumn 4, Issue 1, 2013, Pages 92-103

  Sano, Yasuteru ^a   Kashiwamura, Yoko ^a   Abe, Masaaki ^a   Dieu, Le Ha ^b   Huwyler, Jörg ^b   Shimizu, Fumitaka ^a   Haruki, Hiroyo ^a   Maeda, Toshihiko ^a   Saito, Kazuyuki ^a   Tasaki, Ayako ^a   Kanda, Takashi ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Blood brain barrier; Telomerase; Temperaturesensitive SV40 large T antigen; Tight junction; Transporter

Indexed keywords

TELOMERASE REVERSE TRANSCRIPTASE; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD BRAIN BARRIER; CELL IMMORTALIZATION; CELL LINE; CELL MATURATION; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CELL TRANSPORT; CONTROLLED STUDY; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROPHILICITY; HYDROPHOBICITY; MICROVASCULAR ENDOTHELIAL CELL; MORPHOLOGY; PRIORITY JOURNAL; TEMPERATURE;

EID: 84880015172     PISSN: None     EISSN: 17591961     Source Type: Journal    
DOI: 10.1111/cen3.12001     Document Type: Article

References (37)

1. Engelhardt B. T cell migration into the central nervous system during health and disease: different molecular keys allow access to different central nervous system compartments. Clin Exp Neuroimmunol. 2010; 1: 79-93.
2. Engelhardt B, Sorokin L. The blood-brain and the bloodcerebrospinal fluid barriers: function and dysfunction. Semin Immunopathol. 2009; 31: 497-511.
3. Joó F. Endothelial cells of the brain and other systems: some similarities and differences. Prog Neurobiol. 1996; 48: 255-73.
4. Pardridge, W.M . The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005; 2: 3-14.
5. Perrière N, Yousif S, Cazaubon S, Chaverot N, Bourasset F, Cisternino S, et al. A functional in vitro model of rat blood-brain barrier for molecular analysis of efflux transporters. Brain Res. 2007; 1150: 1-13.
6. Terasaki T, Ohtsuki S, Hori S, Takanaga H, Nakashima E., Hosoya K. New approaches to in vitro models of bloodbrain barrier drug transport. Drug Discov Today. 2003; 8: 944-54.
7. Wilhelm I, Fazakas C, Krizbai IA. In vitro models of the blood-brain barrier. Acta Neurobiol Exp(Wars). 2011; 71: 113-28.
8. Weksler BB, Subileau EA, Perrière N, Charneau P, Holloway K, Leveque M, et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 2005; 19: 1872-4.
9. Sano Y, Shimizu F, Abe M, Maeda T, Kashiwamura Y, Ohtsuki S, et al. Establishment of a new conditionally immortalized human brain microvascular endothelial cell line retaining an in vivo blood-brain barrier function. J Cell Physiol. 2010; 225: 519-28.
10. Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S, Tsukita S, et al. Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol. 1993; 123: 1777-88.
11. Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol. 2003; 161: 653-60.
12. Ohtsuki S, Sato S, Yamaguchi H, Kamoi M, Asashima T, Terasaki T. Exogenous expression of claudin-5 induces barrier properties in cultured rat brain capillary endothelial cells. J Cell Physiol. 2007; 210: 81-6.
13. Biernacki K, Prat A, Blain M, Antel JP. Regulation of cellular and molecular trafficking across human brain endothelial cells by Th1- and Th2-polarized lymphocytes. J Neuropathol Exp Neurol. 2004; 63: 223-32.
14. Yeung D, Manias JL, Stewart DJ, Nag S. Decreased junctional adhesion molecule-A expression during bloodbrain barrier breakdown. Acta Neuropathol. 2008; 115: 635-42.
15. Hirase T, Staddon JM, Saitou M, Ando-Akatsuka Y, Itoh M, Furuse M, et al. Occludin as a possible determinant of tight junction permeability in endothelial cells. J Cell Sci. 1997; 110: 1603-13.
16. Liu J, Jin X, Liu KJ, Liu W. Matrix metalloproteinase-2-mediated occludin degradation and caveolin-1-mediated claudin-5 redistribution contribute to blood-brain barrier damage in early ischemic stroke stage. J Neurosci. 2012; 32: 3044-57.
17. Poller B, Gutmann H, Krähenbühl S, Weksler B, Romero I, Courand PO, et al. The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies. J Neurochem. 2008; 107: 1358-68.
18. Cornford EM, Hyman S, Swartz BE. The human brain GLUT1 glucose transporter: ultrastructural localization to the blood-brain barrier endothelia. J Cereb Blood Flow Metab. 1994; 14: 106-12.
19. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem. 1998; 273: 23629-32.
20. O'Kane RL, Viña JR, Simpson I, Zaragozá R, Mokashi A, Hawkins RA. Cationic amino acid transport across the blood-brain barrier is mediated exclusively by system y+. Am J Physiol Endocrinol Metab. 2006; 291: E412-9.
21. Kido Y, Tamai I, Okamoto M, Suzuki F, Tsuji A. Functional clarification of MCT1-mediated transport of monocarboxylic acids at the blood-brain barrier using in vitro cultured cells and in vivo BUI studies. Pharm Res. 2000; 17: 55-62.
22. Ohtsuki S, Tachikawa M, Takanaga H, Shimizu H, Watanabe M, Hosoya K, et al. The blood-brain barrier creatine transporter is a major pathway for supplying creatine to the brain. J Cereb Blood Flow Metab. 2002; 22: 1327-35.
23. Schinkel AH, Wagenaar E, Mol CA, Van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest. 1996; 97: 2517-24.
24. Nies AT, Jedlitschky G, König J, Herold-Mende C, Steiner HH, Schmitt HP, et al. Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience. 2004; 129: 349-60.
25. Cisternino S, Mercier C, Bourasset F, Roux F, Scherrmann JM. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res. 2004; 64: 3296-301.
26. Goldstein S. Replicative senescence: the human fibroblast comes of age. Science. 1990; 249: 1129-33.
27. Campisi J. Replicative senescence: an old lives' tale? Cell. 1996; 84: 497-500.
28. Harley CB, Goldstein S. Cultured human fibroblasts: distribution of cell generations and a critical limit. J Cell Physiol. 1978; 97: 509-16.
29. Allsopp RC, Vaziri H, Patterson C, Goldstein S, Younglai EV, Futcher AB, et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci USA. 1992; 89: 10114-8.
30. Cerni C. Telomeres, telomerase, and myc An update. Mutat Res. 2000; 462: 31-47.
31. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998; 279: 349-52.
32. O'Hare MJ, Bond J, Clarke C, Takeuchi Y, Atherton AJ, Berry C, et al. Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells. Proc Natl Acad Sci USA. 2001; 98: 646-51.
33. Gumbleton M, Audus KL. Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. J Pharm Sci. 2001; 90: 1681-98.
34. Clark DE. In silico prediction of blood-brain barrier permeation. Drug Discov Today. 2003; 8: 927-33.
35. Kelder J, Grootenhuis PD, Bayada DM, Delbressine LP, Ploemen JP. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res. 1999; 16: 1514-9.
36. Waterhouse RN. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol. 2003; 5: 376-89.
37. Van Damme S, Langenaeker W, Und Bultinck P. Prediction of blood-brain partitioning: a model based on ab initio calculated quantum chemical descriptors. J Mol Graph Model. 2008; 26: 1223-36.